96 related articles for article (PubMed ID: 23631828)
1. Identification of potential bladder cancer markers in urine by abundant-protein depletion coupled with quantitative proteomics.
Chen CL; Lin TS; Tsai CH; Wu CC; Chung T; Chien KY; Wu M; Chang YS; Yu JS; Chen YT
J Proteomics; 2013 Jun; 85():28-43. PubMed ID: 23631828
[TBL] [Abstract][Full Text] [Related]
2. Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation.
Hentschel AE; Beijert IJ; Bosschieter J; Kauer PC; Vis AN; Lissenberg-Witte BI; van Moorselaar RJA; Steenbergen RDM; Nieuwenhuijzen JA
Clin Epigenetics; 2022 Feb; 14(1):19. PubMed ID: 35123558
[TBL] [Abstract][Full Text] [Related]
3. Urinary epidermal growth factor is a novel biomarker for early diagnosis of antibody mediated kidney allograft rejection: A urinary proteomics analysis.
Heidari SS; Nafar M; Kalantari S; Tavilani H; Karimi J; Foster L; Moon KM; Khodadadi I
J Proteomics; 2021 May; 240():104208. PubMed ID: 33785428
[TBL] [Abstract][Full Text] [Related]
4. Automated measurement of a constitutive isotype of serum amyloid A/SAA4 and comparison with other apolipoproteins.
Yamada T; Wada A; Yamaguchi T; Itoh Y; Kawai T
J Clin Lab Anal; 1997; 11(6):363-8. PubMed ID: 9406058
[TBL] [Abstract][Full Text] [Related]
5. [Single-Domain Antibodies Used to Pretreat the Human Urinary Proteome in Cancer Biomarker Testing].
Tillib SV; Goryainova OS; Sachko AM; Ivanova TI; Gaas MY; Vorob'ev NV; Kaprin AD; Shegay PV
Mol Biol (Mosk); 2022; 56(4):671-684. PubMed ID: 35964323
[TBL] [Abstract][Full Text] [Related]
6. Exploration of potential biomarkers for early bladder cancer based on urine proteomics.
Zhou X; Xue F; Li T; Xue J; Yue S; Zhao S; Lu H; He C
Front Oncol; 2024; 14():1309842. PubMed ID: 38410113
[TBL] [Abstract][Full Text] [Related]
7. Proteomics Profiling of Bladder Cancer Tissues from Early to Advanced Stages Reveals NNMT and GALK1 as Biomarkers for Early Detection and Prognosis of BCa.
Davalieva K; Kiprijanovska S; Ivanovski O; Trifunovski A; Saidi S; Dimovski A; Popov Z
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834386
[TBL] [Abstract][Full Text] [Related]
8. Proteomic Profiling of Cryoglobulinemia.
Liu P; Wu J; Sun D; Li H; Qi Z; Tang X; Su W; Li Y; Qin X
Front Immunol; 2022; 13():855513. PubMed ID: 35677050
[TBL] [Abstract][Full Text] [Related]
9. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics.
Hüttenhain R; Soste M; Selevsek N; Röst H; Sethi A; Carapito C; Farrah T; Deutsch EW; Kusebauch U; Moritz RL; Niméus-Malmström E; Rinner O; Aebersold R
Sci Transl Med; 2012 Jul; 4(142):142ra94. PubMed ID: 22786679
[TBL] [Abstract][Full Text] [Related]
10. Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses.
Liu JC; Chen YT; Hsieh YJ; Wu CC; Huang MC; Hsu YC; Wu CT; Chen CK; Dash S; Yu JS
Sci Rep; 2021 May; 11(1):9583. PubMed ID: 33953300
[TBL] [Abstract][Full Text] [Related]
11. 96DRA-Urine: A high throughput sample preparation method for urinary proteome analysis.
Tang X; Xiao X; Sun H; Zheng S; Xiao X; Guo Z; Liu X; Sun W
J Proteomics; 2022 Apr; 257():104529. PubMed ID: 35181559
[TBL] [Abstract][Full Text] [Related]
12. Elastolytic activity is associated with inflammation in bladder cancer.
Gruba N; Stachurski L; Lesner A
J Biochem; 2021 Dec; 170(4):547-558. PubMed ID: 34165535
[TBL] [Abstract][Full Text] [Related]
13. Biomarker Candidates for Tumors Identified from Deep-Profiled Plasma Stem Predominantly from the Low Abundant Area.
Tognetti M; Sklodowski K; Müller S; Kamber D; Muntel J; Bruderer R; Reiter L
J Proteome Res; 2022 Jul; 21(7):1718-1735. PubMed ID: 35605973
[TBL] [Abstract][Full Text] [Related]
14. Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics.
Carvalho LB; Capelo JL; Lodeiro C; Dhir R; Pinheiro LC; López-Fernández H; Martins G; Medeiros M; Díaz F; Santos HM
Commun Med (Lond); 2023 Jan; 3(1):8. PubMed ID: 36646893
[TBL] [Abstract][Full Text] [Related]
15. A Label-Free Proteomic Approach for the Identification of Biomarkers in the Exosome of Endometrial Cancer Serum.
Sommella E; Capaci V; Aloisio M; Salviati E; Campiglia P; Molinario G; Licastro D; Di Lorenzo G; Romano F; Ricci G; Monasta L; Ura B
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551747
[TBL] [Abstract][Full Text] [Related]
16. Urinary Microbiome Dysbiosis and Immune Dysregulations as Potential Diagnostic Indicators of Bladder Cancer.
Uzelac M; Xin R; Chen T; John D; Li WT; Rajasekaran M; Ongkeko WM
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254883
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of methods for enriching urine proteins].
Teng H; Cui Y; Wang Y; Pang Y; Li Q
Sheng Wu Gong Cheng Xue Bao; 2021 Nov; 37(11):4102-4110. PubMed ID: 34841810
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in mass spectrometry-based urinary proteomics.
Joshi N; Garapati K; Ghose V; Kandasamy RK; Pandey A
Clin Proteomics; 2024 Feb; 21(1):14. PubMed ID: 38389064
[TBL] [Abstract][Full Text] [Related]
19. Advances in urinary protein biomarkers for urogenital and non-urogenital pathologies.
Pedroza-Díaz J; Röthlisberger S
Biochem Med (Zagreb); 2015; 25(1):22-35. PubMed ID: 25672464
[TBL] [Abstract][Full Text] [Related]
20. Urinary protein changes during the short-term growth and development of rats.
Liu Y; Yang M; Wang H; Chen Y; Gao Y
Heliyon; 2024 Feb; 10(3):e24555. PubMed ID: 38317946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
